Founded in 1993 through brothers Tom and David Gardner, The Motley Fool is helping millions of others gain monetary freedom through our website, podcasts, books, newspaper columns, radio screens and high-level investment services.
World Health Organization chief scientist Soumya Swaminathan believes he is most likely a leading candidate in the race to expand a COVID-19 vaccine. This leader is AZD1222, the vaccine candidate who opposes the new coronavirus that develops through AstraZeneca (NYSE: AZN) and the University of Oxford.
And the world now knows more about the protection and effectiveness of AZD1222. AstraZeneca announced on Monday the provisional effects of an ongoing phase 1/2 clinical trial of the coVID-19 experimental vaccine. Provisional effects were published in The Lancet. Here are 3 key things to know about the news from AstraZeneca.
Perhaps the maximum expected metric in Phase 1 examines in AZD1222 the number of patients who generated neutralizing antibodies. Neutralizing antibodies have the possibility of preventing infection with SARS-CoV-2, the new guilty coronavirus of COVID-19.
The Lancet results involve 32 of the 35 participants (91%) tested neutralizing antibodies one month after receiving an injection of AZD1222. The 10 patients who gained a momentary dose of the experimental vaccine had neutralizing antibodies.
Professor Andrew Pollard of the University of Oxford, who is the study’s lead researcher, said: “The immune reactions observed after vaccination are in line with what we expect to relate to coverage opposed to the SARS-CoV-2 virus.” He added that the strong immune reaction observed in participants who won two doses of AZD1222 indicates “that this may be a smart vaccination strategy.”
Sometimes it is difficult, as it should be, to compare the effects of clinical trials of one candidate vaccine with another. However, in fact there will be attempts to accumulate the effects of AZD1222 against mNSA-1273 of Modern’s COVID-19 candidate vaccine. Moderna’s actions soared last week after the effects of a Phase 1 mRN-1273 review were published in the New England Journal of Medicine. These effects showed that neutralizing antibodies were produced in the forty-five participants examined after the mNSA-1273 moment dose.
Another thing researchers are interested in in the effects of COVID-19 candidate vaccines is the T-cell response. T cells are white blood cells that play a key role in the body’s immune response. T-cell responses would likely play a vital role in protecting against SARS-CoV-2 infection.
Although it is not yet known precisely how T cells are involved in combating the new coronavirus, studies suggest that the possibility of a T-cell reaction is a factor in reducing the severity of COVID-19. Previous studies have shown that some other people inflamed with the new coronavirus who had no symptoms developed a physically powerful T-cell reaction even if they did not have detectable antibodies.
So how did AZD1222 do it on this front? Very well. AstraZeneca stated that a T-cell reaction induced all clinical study participants. These reactions peaked on the 14th day after the injection, but were maintained for two months. Mene Pangalos, executive vice president of biopharmaceutical studies and progressionArray at AstraZeneca, said the company “encouraged” through the intermediate data; namely, he noticed the reaction of the T cells.
Preliminary knowledge of the immune reaction would not mean much if AZD1222 caused serious adverse events. However, that is not the case.
There were no yellow protection flags in the intermediate results. Pollard said in a statement that “the provisional knowledge of Phase I/II of our coronavirus vaccine shows that the vaccine did not cause any unforeseen reactions and had a protective profile similar to previous vaccines of this type.”
This does not mean that no adverse reactions have been observed. AZD1222 reactions in the study included transient pain and injection site tenderness, mild to moderate headaches, chills, fatigue, fever, discomfort and muscle pain. However, these reactions were mitigated by administering acetaminophen to participants. Adverse effects also occurred less after participants gained the second dose of AZD1222.
Phase 1/2 for which interim effects have been reported is still ongoing. However, AstraZeneca and the University of Oxford have also introduced phase 2/3 clinical trials on AZD1222 in the UK, Brazil and South Africa. A COVID-19 candidate vaccine complex will also begin early in the United States.
AstraZeneca argues that these complex studies will succeed. The company will supply more than 2 billion doses of AZD1222 to comply with its agreements with the United Kingdom, the United States and several non-profit organizations.
Although the provisional effects for Phase 1/2 for AZD1222 were positive, AstraZeneca’s inventories slipped the Monday after the knowledge published in The Lancet. But pharmaceutical inventory can have a major catalyst when complex effects are announced in a few months.